source
- Sensorion drops OTOF gene therapy to focus on GJB2-targeted hearing loss candidate after Regeneron approvalSensorion said it is ending development of its gene therapy SENS-501 for OTOF related hearing loss after a strategic review. The review concluded that the competitive landscape had changed signific…
- Sensorion halts development of SENS-501 for OTOF-related hearing loss after strategic reviewSensorion announced it is ending the development of its SENS-501 candidate, which was aimed at treating OTOF-related hearing loss, following a strategic review of its pipeline. The biotech said it…